Our Durable Core—approximately $14 billion of our FY 2021 revenue—consists of our well-known products and solutions that form the backbone of healthcare around the world: blood collection tubes, ports and catheters; syringes; urinary catheters; acute care pumps and IV sets; hernia mesh; and blood culture testing. The Durable Core touches 90 percent of people in the hospital with 45 billion medical devices each year. The performance of our Durable Core fuels our investments in Transformative Solutions, which constitute about $4 billion of our FY 2021 revenue. These are advances in higher-growth spaces that are transforming the future of global healthcare and that we are targeting with our R&D and M&A investments. The future of healthcare is changing, and we see three irreversible forces that are going to be shaping healthcare in new ways. • Smart c onnected care : Artificial Intelligence (AI), informatics and robotics will transform healthcare processes, tools and treatments. • A shift to ne w care settings : Care is moving increasingly to surgery centers, ambulatory centers, retail clinics and the home, a trend accelerated during the COVID-19 pandemic. This is creating significant opportunities for us to reinvent solutions that will improve patient outcomes in these settings, while lowering costs. • Chr onic disease outcomes : Improving outcomes in chronic disease is a leading global health priority. Although it is traditionally addressed by the pharmaceutical industry with treatment through medication, BD has tackled infectious disease challenges and looks forward to stepping up in a meaningful way, using technology innovation to positively impact chronic disease treatment. Two axes of growth: durable core and transformative solutions Backbone of healthcare Reinventing the future of healthcare Smart connected care AI, informatics and robotics will transform healthcare processes, tools and treatments. New care settings Shift into new settings creates major opportunities to improve patient outcomes and costs. Chronic disease outcomes Medical technology will have a growing role in improving outcomes in chronic diseases. 5 FY21 revenue excluding $2.0 billion of COVID-only testing. Refer to the BD Q4 FY21 earnings presentation for a reconciliation back to GAAP revenue. ~$14B 5 Durable core ~$4B 5 Transformative solutions 15 2021 ESG Report Appendices Transparency Healthy workforce and communities Responsible supply chain Product impact Climate change Introduction